At a glance
An IGF-related research term that requires careful molecular identification.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes tissue-repair and cell-proliferation models. Check which construct was tested before applying a finding to a vial labeled MGF.[1][8][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of MGF.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 100 mcg (0.1 mg) | 6 units (0.06 mL) |
| Week 2 | 150 mcg (0.15 mg) | 9 units (0.09 mL) |
| Week 3 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Week 4 | 250 mcg (0.25 mg) | 15 units (0.15 mL) |
| Weeks 5–8 | 300 mcg (0.3 mg) | 18 units (0.18 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units manageable for accuracy. For ≤10‑unit (≤0.10 mL) administrations during early titration, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support tissue repair and regenerative processes through localized growth factor signaling[3][4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100 mcg daily; increase by ~50 mcg weekly as tolerated.
- Target: 250–300 mcg daily by Weeks 4–8.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within approximately 30 days[4].
Storage Instructions
Proper storage preserves peptide quality[4][5].
- Lyophilized: Store at −20 °C (−4 °F) or colder for long‑term; refrigerate at 4 °C (39.2 °F) for short‑term.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) by at least 1–1.5 inches from prior sites to avoid irritation[10].
- Use 23–25 gauge, 5/8‑inch needles for subcutaneous administration[6].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (MGF, 5 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 5 vials
- 16 weeks ≈ 8 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Journal of Molecular Endocrinology (2003) — Expression of IGF‑I splice variants and structural genes in repair of rabbit tendon (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Sigma‑Aldrich — Storage and handling of synthetic peptides (stability and reconstitution guidelines) (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 05
Source document
R&D Systems — Recombinant human LR3 IGF‑I protein datasheet (storage and stability recommendations) (opens in a new tab)resources.rndsystems.com
Back to overview ↑ - 07
- 08
Research publication
Experimental Cell Research (2008) — MGF E‑peptide activates human muscle satellite cells (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (site rotation and technique) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.